Why ImmunityBio, Inc. (IBRX) Went Up On Wednesday?
We recently published a list of 10 Stocks Stand Strong Amid Cautious Market Environment. In this article, we are going to ...
Garmin Posts Better-Than-Expected Results, Joins SolarEdge Technologies, Compass, Appian And Other Big Stocks Moving Higher On Wednesday
Garmin reported fiscal fourth-quarter 2024 revenue growth of 23% year-on-year to $1.82 billion, beating the analyst consensus estimate of $1.70 billion. The GPS navigation and wearable technology ...
Why ImmunityBio (IBRX) Is Surging Today
ImmunityBio (IBRX) is jumping 20% after the drug maker reported that the FDA had approved its use of an “alternative source ...
FDA authorizes ImmunityBio to provide rBCG to urologists amid shortages
ImmunityBio (IBRX) announced the U.S. Food and Drug Administration FDA has authorized an expanded access program EAP that will bring a vital ...
FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA ...
Optimism In War On Cancer On The Rise, As Biotech Companies Roll Out More Wins - Financial News Media
CONTINUED... Read this and more news for Oncolytics Biotech at: In other recent industry developments and happenings in the m ...
Optimism in War on Cancer on the Rise, as Biotech Companies Roll Out More Wins
Detailed price information for Immunitybio Inc (IBRX-Q) from The Globe and Mail including charting and trades.
ImmunityBio’s (IBRX) Buy Rating Reiterated at D. Boral Capital
D. Boral Capital restated their buy rating on shares of ImmunityBio (NASDAQ:IBRX – Free Report) in a report released on Friday,Benzinga reports. They currently have a $30.00 price target on the stock.
Stagwell’s (STGW) “Buy” Rating Reiterated at Rosenblatt Securities
Rosenblatt Securities restated their buy rating on shares of Stagwell (NASDAQ:STGW – Free Report) in a research report sent to investors on Friday morning,Benzinga reports. They currently have a $9.00 ...
ImmunityBio announces UK acceptance of Anktiva marketing application
ImmunityBio (IBRX) announced the Medicines and Healthcare products Regulatory Agency has validated and accepted the marketing authorization ...